

Nickel-catalyzed *ortho*-halogenation of unactivated (hetero)aryl C–H bonds with lithium halides using a removable auxiliary

Bei-Bei Zhan, Yan-Hua Liu, Fang Hu and Bing-Feng Shi*

E-mail: bfshi@zju.edu.cn

Department of Chemistry, Zhejiang University, Hangzhou 310027, China

Supporting Information

Table of Contents:


1. General information	S2
2. Experimental Section	S2
2.1 Preparation of 2-(Pyridin-2-yl)isopropyl (PIP) Amine	S2
2.2 General Procedure for the Preparation of Starting Materials	S3
2.3 Optimization of Reaction Conditions	S4
2.4 General Procedure for the Halogenations	S6
2.5 Removal of the Directing Group	S19
3. References	S20
4. Spectra	S21

1. General Information

t-BuCN was dried by CaH₂, distilled under reduced pressure and stored under nitrogen. Ni(OTf)₂ and LiI were obtained from Energy[®]. LiBr, LiCl and tetrahydropyran were obtained from Aladdin. NiCl₂(PPh₃)₂ was obtained from SINOCOMPOUND. Dibutyl ether was obtained from Adamas. The other materials and solvents were purchased from Aladdin and other commercial suppliers and used without additional purification. NMR spectra were recorded on a Bruker Avance operating for ¹H NMR at 400 MHz, ¹³C NMR at 100 MHz, and ¹⁹F NMR at 376 MHz, using TMS as internal standard. The peaks were internally referenced to CDCl₃ (7.26 ppm) or residual undeuterated solvent signal (77.20 ppm for ¹³C NMR). The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, m = multiplet, b = broad. Mass spectroscopy data of the products were collected on an HRMS-TOF instrument or a low-resolution MS instrument using EI ionization.

2. Experimental Section

2.1 Preparation of 2-(Pyridin-2-yl)isopropyl (PIP) Amine




An improvement of the work-up procedure to the literature^[1] was used: To a solution of 2-cyanopyridine (33.0 g, 0.32 mol) in 500 ml of toluene was added CH₃MgBr (3.2M in 2-methyl tetrahydrofuran, 300ml, 0.96mol) dropwise at 0°C in a nitrogen atmosphere by vigorous magnetometric stirring. Upon completion of addition, the mixture was refluxed overnight. The reaction was quenched by adding saturated aqueous NH₄Cl dropwise at 0°C until the dark mixture changed to yellow. The suspension was filtrated through a pad of celite[®] and the filtration was acidified by aqueous HCl (6 M, 10 ml). The resulting water phase combined with the filter residue was basified by saturated aqueous NaOH until the yellow colored mixture turned dark brown with slurry sticky to the bottom. The mixture was washed with dichloromethane (500 ml×4) carefully and

the organic phase was combined and concentrated using a rotary evaporator. The crude product was further purified by distillation under reduced pressure. The target product was obtained as a light yellow liquid (>98% purity. 24g, 55%). ¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 4.2 Hz, 1 H), 7.63 (td, *J* = 7.8, 1.8 Hz, 1 H), 7.45 (d, *J* = 8.0 Hz, 1 H), 7.12 (ddd, *J* = 7.4, 4.8, 0.8 Hz, 1 H), 1.87 (s, 2 H), 1.50 (s, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 168.32, 148.78, 136.55, 121.41, 118.53, 54.14, 31.35.


2.2 General Procedure for the Preparation of Starting Materials

General Procedure for the Preparation of Starting Materials (Method A):



A solution of an acid (5 mmol) was refluxed in 5 mL SOCl₂ for 2h and cooled to RT. The excess of SOCl₂ was removed under vacuum to give corresponding acid chloride. The acid chloride was then re-dissolved in 5 mL dry CH₂Cl₂ and added dropwise to a 20 mL dry CH₂Cl₂ solution containing amine (5 mmol) and Et₃N (10 mmol) at 0 °C. After stirring for 6h at ambient temperature, the resulting mixture was washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give the desired product.


General Procedure for the Preparation of Starting Materials (Method B):



A mixture of amine (5 mmol), 6-bromohexanoic acid (5 mmol), EDCI (5.5 mmol) and HOBT (5.5 mmol) in anhydrous DMF (20 mL) was stirred at room temperature overnight. Water was added and the mixture was extracted with diethyl ether. The combined organic layer was washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography to give the desired product.

2.3 Optimization of Reaction Conditions


Screening of Oxidants



Entry ^a	Oxidant (2.0 eq.)	Yield ^b of 2a
1	PhI(OAc) ₂	decomposed
2	K ₂ S ₂ O ₈	decomposed
3	Selectfluor	decomposed
4	KMnO ₄ (2.2 eq.)	58%
5	BQ	N.R.
6	Ag ₂ CO ₃	trace
7	TBHP	trace

^a The reactions were carried out **1a** (0.1 mmol), Ni(OTf)₂ (0.01 mmol), LiBr (0.3 mmol), oxidant (0.2 mmol), *t*-BuCN (0.5 mL), O₂, 140 °C. ^b ¹H NMR yield using CH₂Br₂ as the internal standard.


Screening of Solvents



Entry ^a	Solvent	Yield ^b of 2a
1	dioxane	trace
2	CH ₃ OH	N.R.
3	DCE	40%
4	<i>t</i> -BuCN	58%
5	toluene	18%

^a The reactions were carried out **1a** (0.1 mmol), Ni(OTf)₂ (0.01 mmol), LiBr (0.3 mmol), KMnO₄ (0.22 mmol), solvent (0.5 mL), O₂, 140 °C. ^b ¹H NMR yield using CH₂Br₂ as the internal standard.


Screening of Nickel Catalysts



Entry ^a	[Ni]	Yield ^b of 2a
1	/	N.R.
2	$\text{Ni}(\text{OAc})_2$	29%
3	$\text{Ni}(\text{OTf})_2$	60%
4	$\text{Ni}(\text{acac})_2$	22%
5	NiBr_2	trace

^a The reactions were carried out **1a** (0.1 mmol), $[\text{Ni}]$ (0.01 mmol), LiBr (0.3 mmol), KMnO_4 (0.22 mmol), $t\text{-BuCN}$ (0.5 mL), O_2 , 140 °C. ^b ^1H NMR yield using CH_2Br_2 as the internal standard.


Screening of Ligands



Entry ^a	Ligand	Yield ^b of 2a
1	PPh_3	trace
2	PCy_3	60%
3	DME	20%
4	THP	92% ^c
5	DBE	47%


^a The reactions were carried out **1a** (0.1 mmol), $\text{Ni}(\text{OTf})_2$ (0.01 mmol), LiBr (0.3 mmol), KMnO_4 (0.22 mmol), $t\text{-BuCN}$ (0.5 mL), O_2 , 140 °C. ^b ^1H NMR yield using CH_2Br_2 as the internal standard. ^c Isolated yield. DME = glycol dimethyl ether, THP = tetrahydropyran, DBE = dibutylether.

2.4 General Procedure for the Halogenations




To a 50 mL sealed tube was added substrate (0.1mmol), nickel catalyst (3.7 mg, 0.01mmol), L (0.02mmol), LiX (0.3mmol), KMnO₄ (36mg, 0.22mmol), and *t*-BuCN (0.5 mL). The mixture was stirred at 140°C oil bath for 24 hour. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and quenched with saturated ammonia solution. The aqueous phase was extracted with ethyl acetate (10 mL × 3). The combined organic phase was dried with anhydrous magnesium sulfate. After concentration, the resulting residue was purified by flash chromatography to afford the product.

2-Bromo-6-chloro-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (2a)



¹H NMR (400 MHz, CDCl₃) δ 8.45 (d, *J* = 4.8 Hz, 1H), 8.25 (brs, 1H), 7.74 (td, *J* = 8.0, 1.6 Hz, 1H), 7.48 (d, *J* = 8.4 Hz, 2H), 7.36 (d, *J* = 8.0 Hz, 1H), 7.18 (m, 2H), 1.92 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 164.3, 163.9, 147.5, 138.9, 137.4, 132.3, 131.3, 130.6, 128.7, 122.1, 120.8, 119.7, 57.7, 27.4; HRMS (EI-TOF) calcd for C₁₅H₁₄BrClN₂O (M⁺): 351.9978, found: 351.9980.


2-Bromo-6-fluoro-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (2b)



¹H NMR (400 MHz, CDCl₃) δ 8.46 (dd, *J* = 4.8, 0.8 Hz, 1H), 8.26 (brs, 1H), 7.74 (td, *J* = 8.0, 1.6 Hz, 1H), 7.47 (d, *J* = 8.4 Hz, 1H), 7.38 (d, *J* = 8.4 Hz, 1H), 7.25 – 7.17 (m, 2H), 7.08 (td, *J* = 8.4, 0.8 Hz, 1H), 1.91 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 164.0,


162.4, 160.8, 158.3, 147.6, 137.4, 131.0(d, $J = 8.0$ Hz), 128.97 – 128.46 (m), 122.2, 120.9 (d, $J = 5.0$ Hz), 119.6, 115.2, 115.0, 57.8, 27.5; HRMS (EI-TOF) calcd for $C_{15}H_{14}BrFN_2O$ (M^+): 336.0274, found:336.0275.

2-Bromo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (2c)




1H NMR (400 MHz, $CDCl_3$) δ 8.48 – 8.46 (m, 1H), 8.24 (brs, 1H), 7.75 – 7.71 (m, 1H), 7.59 (dd, $J = 8.0, 0.8$ Hz, 1H), 7.54 (dd, $J = 7.6, 1.6$ Hz, 1H), 7.47 (dt, $J = 8.0, 0.8$ Hz, 1H), 7.35 (td, $J = 7.6, 1.2$ Hz, 1H), 7.28 – 7.22 (m, 1H), 7.19 (ddd, $J = 7.2, 4.8, 0.8$ Hz, 1H), 1.90 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 167.1, 164.3, 147.7, 139.5, 137.3, 133.4, 130.9, 129.3, 127.6, 122.1, 119.6, 57.6, 27.6; HRMS (EI-TOF) calcd for $C_{15}H_{15}BrN_2O_2$ (M^+):318.0368, found: 318.0367.

2,6-dibromo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (2c')



1H NMR (400 MHz, $CDCl_3$) δ 8.46 (d, $J = 4.8$ Hz, 1H), 8.28 (brs, 1H), 7.74 (td, $J = 8.0, 1.6$ Hz, 1H), 7.53 (d, $J = 8.0$ Hz, 2H), 7.49 (d, $J = 8.0$ Hz, 1H), 7.20 (dd, $J = 6.8, 4.8$ Hz, 1H), 7.09 (t, $J = 8.0$ Hz, 1H), 1.93 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 165.2, 164.0, 147.6, 140.8, 137.4, 132.0, 131.0, 122.2, 120.8, 119.7, 57.7, 27.4; HRMS (EI-TOF) calcd for $C_{15}H_{14}Br_2N_2O$ (M^+): 395.9473, found:395.9479.


2,6-Dibromo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (2d)



1H NMR (400 MHz, $CDCl_3$) δ 8.46 (d, $J = 4.8$ Hz, 1H), 8.28 (brs, 1H), 7.74 (td, $J = 8.0, 1.6$ Hz, 1H), 7.53 (d, $J = 8.0$ Hz, 2H), 7.49 (d, $J = 8.0$ Hz, 1H), 7.20 (dd, $J = 6.8, 4.8$ Hz, 1H), 7.09 (t, $J = 8.0$ Hz, 1H), 1.93 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 165.2, 164.0, 147.6, 140.8, 137.4, 132.0, 131.0, 122.2, 120.8, 119.7, 57.7, 27.4; HRMS (EI-TOF)


calcd for C₁₅H₁₄Br₂N₂O (M⁺): 395.9473, found:395.9479.

2-Bromo-5-methoxy-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2e)




¹H NMR (400 MHz, CDCl₃) δ 8.47 (dd, *J* = 4.8, 0.8 Hz, 1H), 8.18 (brs, 1H), 7.78 – 7.68 (m, 2H), 7.47 (d, *J* = 8.4 Hz, 1H), 7.19 (ddd, *J* = 7.6, 4.8, 0.8 Hz, 1H), 7.02 (d, *J* = 3.2 Hz, 1H), 6.68 (dd, *J* = 8.8, 2.8 Hz, 1H), 3.80 (s, 3H), 1.91 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 166.8, 164.2, 159.1, 147.8, 140.1, 137.3, 134.2, 122.1, 119.7, 117.5, 114.5, 109.8, 57.6, 55.8, 27.6; HRMS (EI-TOF) calcd for C₁₆H₁₇BrN₂O₂ (M⁺): 348.0473, found: 348.0475.

2,5-Dibromo-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2f)



¹H NMR (400 MHz, CDCl₃) δ 8.52 – 8.45 (m, 1H), 8.35 (brs, 1H), 7.74 (td, *J* = 8.0, 1.6 Hz, 1H), 7.65 (d, *J* = 2.4 Hz, 1H), 7.46 (d, *J* = 4.0 Hz, 1H), 7.44 (d, *J* = 4.4 Hz, 1H), 7.37 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.21 (ddd, *J* = 7.2, 4.8, 0.8 Hz, 1H), 1.88 (s, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 165.5, 164.0, 147.7, 141.2, 137.5, 134.9, 133.8, 132.2, 122.3, 121.6, 119.7, 118.4, 57.7, 27.5; HRMS (EI-TOF) calcd for C₁₅H₁₄Br₂N₂O (M⁺): 395.9473, found:395.9468.


2-Bromo-4-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2g)



¹H NMR (400 MHz, CDCl₃) δ 8.48 (dd, *J* = 4.8, 0.4 Hz, 1H), 8.33 (brs, 1H), 7.74 (td, *J* = 8.0, 2.0 Hz, 1H), 7.56 (dd, *J* = 8.8, 6.0 Hz, 1H), 7.46 (d, *J* = 8.0 Hz, 1H), 7.34 (dd, *J* = 8.4, 2.8 Hz, 1H), 7.20 (ddd, *J* = 7.2, 4.8, 0.8 Hz, 1H), 7.07 (td, *J* = 8.4, 2.4 Hz, 1H),


1.89 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.2, 164.1(d, $J = 13.0$ Hz), 161.5, 147.7, 137.4, 135.8 (d, $J = 3.6$ Hz), 130.9(d, $J = 8.8$ Hz), 122.2, 120.8, 120.6, 120.3 (d, $J = 9.6$ Hz), 119.7, 115.0, 114.8, 57.6, 27.6; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{BrFN}_2\text{O}$ (M^+): 336.0274, found:336.0276.

2,6-Dibromo-4-fluoro-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2g')




^1H NMR (400 MHz, CDCl_3) δ 8.46 (d, $J = 4.8$ Hz, 1H), 8.32 (brs, 1H), 7.75 (td, $J = 7.6$, 2.0 Hz, 1H), 7.47 (d, $J = 8.0$ Hz, 1H), 7.31 (d, $J = 8.0$ Hz, 2H), 7.23 – 7.18 (m, 1H), 1.92 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.6, 163.9, 163.0, 160.5, 147.5, 137.5 (d, $J = 5.5$ Hz), 122.3, 121.1 (d, $J = 10.2$ Hz), 119.7 (d, $J = 6.5$ Hz), 119.5, 57.7, 27.3; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{Br}_2\text{FN}_2\text{O}$ (M^+): 413.9379, found:413.9375.

2,4-Dibromo-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2h)



^1H NMR (400 MHz, CDCl_3) δ 8.47 (d, $J = 4.8$ Hz, 1H), 8.35 (brs, 1H), 7.80 – 7.71 (m, 2H), 7.52 – 7.43 (m, 2H), 7.41 (d, $J = 8.4$ Hz, 1H), 7.20 (dd, $J = 7.2$, 4.8 Hz, 1H), 1.88 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ 166.2, 164.0, 147.7, 138.3, 137.5, 135.8, 130.8, 130.5, 123.9, 122.2, 120.4, 119.7, 57.6, 27.5; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{Br}_2\text{N}_2\text{O}$ (M^+): 395.9473, found:395.9469.


2,4,6-Tribromo-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2h')



^1H NMR (400 MHz, CDCl_3) δ 8.45 (d, $J = 4.4$ Hz, 1H), 8.36 (brs, 1H), 7.74 (t, $J = 7.6$ Hz, 1H), 7.71 (s, 2H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.20 (t, $J = 6.0$ Hz, 1H), 1.91 (s, 6H);


^{13}C NMR (100 MHz, CDCl_3) δ 164.5, 163.8, 147.5, 139.8, 137.5, 134.4, 123.2, 122.3, 121.2, 119.7, 57.7, 27.3; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{13}\text{Br}_3\text{N}_2\text{O}$ (M^+): 473.8578, found: 473.8573.

2-Bromo-4-iodo-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2i)




^1H NMR (400 MHz, CDCl_3) δ 8.47 (d, $J = 4.4$ Hz, 1H), 8.38 (brs, 1H), 7.97 (s, 1H), 7.74 (t, $J = 8.0$ Hz, 1H), 7.69 (d, $J = 8.0$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.31 – 7.25 (m, 1H), 7.22 – 7.16 (m, 1H), 1.89 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.2, 164.1, 147.7, 141.4, 139.0, 137.4, 136.7, 130.5, 122.2, 120.4, 119.6, 95.6, 57.6, 27.5; HRMS (ESI-TOF) calcd for $\text{C}_{15}\text{H}_{15}\text{BrIN}_2\text{O}$ [$\text{M}+\text{Na}$] $^+$: 466.9226, found: 466.9222.

2,6-Dibromo-4-iodo-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2i')



^1H NMR (400 MHz, CDCl_3) δ 8.45 (d, $J = 4.4$ Hz, 1H), 8.36 (brs, 1H), 7.89 (s, 2H), 7.74 (t, $J = 7.6$ Hz, 1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.23 – 7.18 (m, 1H), 1.91 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.5, 163.9, 147.5, 140.4, 139.9, 137.5, 122.3, 121.2, 119.7, 94.4, 57.7, 27.3; HRMS (ESI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{Br}_2\text{IN}_2\text{O}$ [M^+H] $^+$: 522.8512, found: 522.8525.


4-acetyl-2-bromo-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (2j)



^1H NMR (400 MHz, CDCl_3) δ 8.53 (d, $J = 4.4$ Hz, 1H), 8.28 (brs, 1H), 8.16 (d, $J = 1.2$ Hz, 1H), 7.95 – 7.85 (m, 2H), 7.65 (d, $J = 8.0$ Hz, 1H), 7.58 (d, $J = 8.0$ Hz, 1H), 7.34 (dd, $J = 6.8$ Hz, $J = 5.2$ Hz, 1H), 2.61 (s, 3H), 1.92 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3)


δ 196.3, 166.5, 163.4, 146.6, 142.7, 139.0, 133.3, 129.6, 127.5, 122.8, 120.3, 120.1, 57.3, 27.5, 26.9. HRMS (EI-TOF) calcd for $C_{17}H_{17}BrN_2O_2$ $[M^+H]^+$: 360.0473, found: 360.0472.

2-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-4-(trifluoromethyl)benzamide (2k)




1H NMR (400 MHz, $CDCl_3$) δ 8.50 – 8.43 (m, 2H), 7.87 (s, 1H), 7.76 (td, J = 8.0, 1.6 Hz, 1H), 7.67 – 7.59 (m, 2H), 7.46 (d, J = 8.1 Hz, 1H), 7.22 (ddd, J = 7.6, 4.8, 0.8 Hz, 1H), 1.91 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 165.9, 163.9, 147.6, 142.9, 137.5, 133.0, 132.7, 130.5 (d, J = 3.9 Hz), 129.6, 124.6 (d, J = 3.7 Hz), 122.3, 120.1, 119.7, 57.7, 27.5. HRMS (ESI-TOF) calcd for $C_{16}H_{14}BrF_3N_2O$ $[M+H]^+$: 387.0314, found: 387.0306.

2,6-dibromo-N-(2-(pyridin-2-yl)propan-2-yl)-4-(trifluoromethyl)benzamide (2k')



1H NMR (400 MHz, $CDCl_3$) δ 8.48 (brs, 1H), 8.46 – 8.42 (m, 1H), 7.85 – 7.71 (m, 3H), 7.47 (d, J = 8.0 Hz, 1H), 7.24 – 7.19 (m, 1H), 1.93 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 164.1, 163.6, 147.5, 143.9, 137.6, 134.1, 133.3, 132.9, 129.0 (q, J = 3.7 Hz), 123.6, 122.3, 121.2, 120.9, 119.6, 57.8, 27.3. HRMS (EI-TOF) calcd for $C_{16}H_{13}BrF_3N_2O$ (M^+): 463.9347, found: 463.9349.


7-bromo-N-(2-(pyridin-2-yl)propan-2-yl)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide (2l)



1H NMR (400 MHz, $CDCl_3$) δ 8.49 (d, J = 4.4 Hz, 1H), 8.15 (brs, 1H), 7.73 (td, J = 8.0,


1.6 Hz, 1H), 7.46 (d, $J = 8.4$ Hz, 1H), 7.19 (dd, $J = 7.2, 5.2$ Hz, 1H), 7.13 (s, 1H), 7.08 (s, 1H), 4.25 (s, 4H), 1.86 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.1, 164.1, 147.5, 145.1, 142.8, 137.2, 132.0, 121.9, 121.6, 119.6, 118.4, 110.0, 64.5, 64.2, 57.3, 27.5. HRMS (EI-TOF) calcd for $\text{C}_{17}\text{H}_{17}\text{Br}_2\text{N}_2\text{O}_3$ $[\text{M}^+\text{H}]^+$: 376.0423, found: 376.0428.

4-Bromo-2,5-dichloro-*N*-(2-(pyridin-2-yl)propan-2-yl)thiophene-3-carboxamide (2p)




^1H NMR (400 MHz, CDCl_3) δ 8.49 (dd, $J = 4.8, 0.8$ Hz, 1H), 8.46 (brs, 1H), 7.75 (td, $J = 7.6, 1.6$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.21 (ddd, $J = 7.2, 4.8, 0.8$ Hz, 1H), 1.88 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.8, 159.9, 147.6, 137.5, 136.3, 126.0, 124.6, 122.3, 119.6, 109.4, 57.7, 27.6; HRMS (EI-TOF) calcd for $\text{C}_{13}\text{H}_{11}\text{BrCl}_2\text{N}_2\text{OS}$ (M^+): 391.9153, found: 391.9148.

3-Bromo-5-chloro-*N*-(2-(pyridin-2-yl)propan-2-yl)thiophene-2-carboxamide (2q)




^1H NMR (400 MHz, CDCl_3) δ 9.17 (brs, 1H), 8.54 (d, $J = 4.8$ Hz, 1H), 7.74 (td, $J = 7.6, 1.2$ Hz, 1H), 7.43 (d, $J = 8.0$ Hz, 1H), 7.21 (dd, $J = 7.2, 5.2$ Hz, 1H), 6.88 (s, 1H), 1.85 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.1, 158.9, 147.8, 137.3, 136.1, 135.1, 131.0, 122.2, 119.5, 107.2, 58.3, 27.7; HRMS (EI-TOF) calcd for $\text{C}_{13}\text{H}_{12}\text{BrClN}_2\text{OS}$ (M^+): 357.9542, found: 357.9545.

3-Bromo-5-nitro-*N*-(2-(pyridin-2-yl)propan-2-yl)thiophene-2-carboxamide (2r)




^1H NMR (400 MHz, CDCl_3) δ 9.63 (brs, 1H), 8.54 (d, $J = 4.4$ Hz, 1H), 7.83 (s, 1H), 7.78 (td, $J = 8.0, 1.2$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.25 (m, 1H), 1.87 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.6, 157.9, 152.4, 147.7, 143.6, 137.6, 132.0, 122.5, 119.6, 107.1, 58.6, 27.5. HRMS (EI-TOF) calcd for $\text{C}_{13}\text{H}_{12}\text{BrN}_3\text{O}_3\text{S}$ (M^+): 368.9783, found: 368.9785.

5-Bromo-2-fluoro-*N*-(2-(pyridin-2-yl)propan-2-yl)isonicotinamide (2s)




^1H NMR (400 MHz, CDCl_3) δ 8.70 (brs, 1H), 8.47 (m, 1H), 8.38 (s, 1H), 7.77 (td, $J = 8.0, 1.6$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.23 (ddd, $J = 7.6, 4.8, 0.8$ Hz, 1H), 7.12 (d, $J = 3.2$ Hz, 1H), 1.89 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.3, 163.5 (d, $J = 3.0$ Hz), 161.8, 150.8 (d, $J = 7.0$ Hz), 150.6 (d, $J = 15.0$ Hz), 147.6, 137.7, 122.5, 119.6, 113.6 (d, $J = 5.0$ Hz), 110.1, 109.7, 57.8, 27.5; HRMS (EI-TOF) calcd for $\text{C}_{14}\text{H}_{13}\text{BrFN}_3\text{O}$ (M^+): 337.0226, found: 337.0230.

2,5-Dibromo-*N*-(2-(pyridin-2-yl)propan-2-yl)isonicotinamide (2t)




^1H NMR (400 MHz, CDCl_3) δ 8.64 (brs, 1H), 8.52 (s, 1H), 8.48 (d, $J = 4.8$ Hz, 1H), 7.77 (td, $J = 8.0, 1.6$ Hz, 1H), 7.60 (s, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.26 – 7.21 (m, 1H), 1.87 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.4, 163.1, 152.8, 148.1, 147.5, 141.0, 137.7, 127.6, 122.4, 119.6, 116.9, 57.8, 27.4; HRMS (EI-TOF) calcd for $\text{C}_{14}\text{H}_{13}\text{Br}_2\text{N}_3\text{O}$ (M^+): 396.9425, found: 396.9427.

2-Chloro-6-iodo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (3a)




^1H NMR (400 MHz, CDCl_3) δ 8.46 (d, $J = 4.8$ Hz, 1H), 8.27 (brs, 1H), 7.75 (m, 2H), 7.48 (d, $J = 8.4$ Hz, 1H), 7.38 (d, $J = 8.0$ Hz, 1H), 7.19 (ddd, $J = 7.2, 4.8, 0.8$ Hz, 1H), 6.99 (t, $J = 8.0$ Hz, 1H), 1.94 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.0, 164.0, 147.5, 142.7, 137.8, 137.4, 131.4, 130.9, 129.6, 122.2, 119.7, 93.8, 57.7, 27.4; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{ClIN}_2\text{O}$ (M^+): 399.9839, found:399.9842.

2-Fluoro-6-iodo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (3b)




^1H NMR (400 MHz, CDCl_3) δ 8.46 (d, $J = 4.8$ Hz, 1H), 8.25 (brs, 1H), 7.78 – 7.70 (m, 1H), 7.63 (d, $J = 7.6$ Hz, 1H), 7.48 (d, $J = 8.4$ Hz, 1H), 7.19 (dd, $J = 7.2, 4.8$ Hz, 1H), 7.13 – 7.02 (m, 2H), 1.92 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.0 (d, $J = 6.0$ Hz), 160.0, 157.5, 147.6, 137.4, 135.2 (d, $J = 3.5$ Hz), 132.5, 132.3, 131.5 (d, $J = 8.3$ Hz), 122.2, 119.7, 116.0, 115.8, 93.9 (d, $J = 3.4$ Hz), 57.8, 27.5. HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{FIN}_2\text{O}$ (M^+): 384.0135, found:384.0133.

2-Iodo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (3c)



^1H NMR (400 MHz, CDCl_3) δ 8.47 (m, 1H), 8.18 (brs, 1H), 7.87 (dd, $J = 8.0, 0.8$ Hz, 1H), 7.74 (td, $J = 7.6, 1.6$ Hz, 1H), 7.50 – 7.43 (m, 2H), 7.38 (td, $J = 7.2, 1.2$ Hz, 1H), 7.19 (ddd, $J = 7.6, 4.8, 0.8$ Hz, 1H), 7.08 (td, $J = 7.6, 1.6$ Hz, 1H), 1.91 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.7, 164.2, 147.7, 143.6, 139.9, 137.4, 130.8, 128.3, 128.2, 122.1, 119.7, 92.8, 57.5, 27.6; The analytical data above were matched with literature.^[2]


2,6-Diiodo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (3c')



^1H NMR (400 MHz, CDCl_3) δ 8.47 (d, $J = 3.6$ Hz, 1H), 8.31 (brs, 1H), 7.81 (d, $J = 8.0$


Hz, 2H), 7.75 (t, $J = 7.6$ Hz, 1H), 7.48 (d, $J = 8.0$ Hz, 1H), 7.24 – 7.15 (m, 1H), 6.72 (t, $J = 8.0$ Hz, 1H), 1.96 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.6, 164.1, 147.9, 147.5, 139.3, 137.4, 131.4, 122.2, 119.8, 92.6, 57.6, 27.2; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{I}_2\text{N}_2\text{O}$ (M^+): 491.9195, found:491.9199.

2-Iodo-5-methoxy-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (3e)




^1H NMR (400 MHz, CDCl_3) δ 8.50 – 8.45 (m, 1H), 8.18 (brs, 1H), 7.77 – 7.68 (m, 2H), 7.47 (d, $J = 8.4$ Hz, 1H), 7.19 (ddd, $J = 7.6, 4.8, 0.8$ Hz, 1H), 7.02 (d, $J = 3.2$ Hz, 1H), 6.68 (dd, $J = 8.8, 2.8$ Hz, 1H), 3.80 (s, 3H), 1.91 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.4, 164.2, 159.9, 147.7, 144.3, 140.6, 137.4, 122.1, 119.7, 117.5, 114.1, 81.0, 57.5, 55.7, 27.6; HRMS (EI-TOF) calcd for $\text{C}_{16}\text{H}_{17}\text{IN}_2\text{O}_2$ (M^+): 396.0335, found:396.0338.

4-Fluoro-2-iodo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (3g)



^1H NMR (400 MHz, CDCl_3) δ 8.47 (d, $J = 4.4$ Hz, 1H), 8.25 (brs, 1H), 7.74 (td, $J = 7.6, 1.6$ Hz, 1H), 7.59 (dd, $J = 8.4, 2.4$ Hz, 1H), 7.50 – 7.41 (m, 2H), 7.24 – 7.17 (m, 1H), 7.09 (td, $J = 8.0, 2.4$ Hz, 1H), 1.90 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.9, 164.13 (s), 163.6, 161.1, 147.7, 139.8 (d, $J = 3.5$ Hz), 137.4, 129.5 (d, $J = 8.5$ Hz), 127.2, 126.9, 122.2, 119.7, 115.5, 115.3, 92.6 (d, $J = 8.2$ Hz), 57.5, 27.5; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{FIN}_2\text{O}$ (M^+): 384.0135, found:384.0137.


4-Bromo-2-iodo-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (3h)



^1H NMR (400 MHz, CDCl_3) δ 8.49 – 8.43 (m, 1H), 8.29 (brs, 1H), 8.02 (d, $J = 1.6$ Hz, 1H), 7.74 (td, $J = 8.0, 2.0$ Hz, 1H), 7.51 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 1H), 7.20 (ddd, $J = 7.6, 4.8, 0.8$ Hz, 1H), 1.89 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.8, 164.0, 147.6, 142.4, 141.9, 137.5, 131.4, 129.2, 123.8,


122.2, 119.7, 93.4, 57.5, 27.5; HRMS (EI-TOF) calcd for $C_{15}H_{14}BrIN_2O$ (M^+): 443.9334, found:443.9331.

2-Iodo-N-(2-(pyridin-2-yl)propan-2-yl)-5-(trifluoromethyl)benzamide (3m)




1H NMR (400 MHz, $CDCl_3$) δ 8.48 (d, $J = 4.4$ Hz, 1H), 8.39 (brs, 1H), 8.01 (d, $J = 8.4$ Hz, 1H), 7.76 (td, $J = 8.0, 1.6$ Hz, 1H), 7.68 (d, $J = 1.6$ Hz, 1H), 7.47 (d, $J = 8.0$ Hz, 1H), 7.33 (dd, $J = 8.4, 2.0$ Hz, 1H), 7.22 (dd, $J = 6.8, 4.8$ Hz, 1H), 1.93 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 167.4, 163.9, 147.6, 144.4, 140.7, 137.5, 131.1, 130.8, 127.2(d, $J = 3.5$ Hz), 124.9 (d, $J = 3.7$ Hz), 122.3, 119.7, 97.3, 57.6, 27.5; HRMS (EI-TOF) calcd for $C_{16}H_{14}F_3IN_2O$ (M^+): 434.0103, found:434.0103.

3-Iodo-N-(2-(pyridin-2-yl)propan-2-yl)-2-naphthamide (3n)




1H NMR (400 MHz, $CDCl_3$) δ 8.47 (d, $J = 4.0$ Hz, 1H), 8.39 (s, 1H), 8.31 (brs, 1H), 7.93 (s, 1H), 7.87 – 7.79 (m, 1H), 7.76 – 7.72 (m, 2H), 7.57 – 7.45 (m, 3H), 7.24 – 7.15 (m, 1H), 1.96 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 168.7, 164.3, 147.7, 140.0, 139.5, 137.4, 134.9, 132.2, 128.3, 127.7, 127.2, 126.8, 122.1, 119.7, 89.5, 57.5, 27.6; HRMS (EI-TOF) calcd for $C_{19}H_{17}IN_2O$ (M^+): 416.0386, found: 416.0385.

2-Chloro-5-iodo-N-(2-(pyridin-2-yl)propan-2-yl)isonicotinamide (3u)




1H NMR (400 MHz, $CDCl_3$) δ 8.74 (s, 1H), 8.58 (brs, 1H), 8.48 (d, $J = 4.8$ Hz, 1H), 7.77 (td, $J = 8.0, 1.6$ Hz, 1H), 7.45 (d, $J = 8.0$ Hz, 1H), 7.41 (s, 1H), 7.26 – 7.21 (m, 1H), 1.90 (s, 6H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 165.0, 163.4, 158.0, 152.4, 151.9, 147.5, 137.7, 123.5, 122.5, 119.65, 89.5, 57.7, 27.4; HRMS (EI-TOF) calcd for $C_{14}H_{13}ClIN_3O$ (M^+): 400.9792, found:400.9788.

4-Iodo-5-methyl-N-(2-(pyridin-2-yl)propan-2-yl)thiophene-3-carboxamide (3v)



^1H NMR (400 MHz, CDCl_3) δ 8.75 (brs, 1H), 8.57 – 8.51 (m, 1H), 7.72 (td, $J=8.0$, 1.6 Hz, 1H), 7.45 (d, $J=8.0$ Hz, 1H), 7.20 (ddd, $J=7.2$, 4.8, 0.8 Hz, 1H), 7.16 (d, $J=0.8$ Hz, 1H), 2.29 (d, $J=0.4$ Hz, 3H), 1.87 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.4, 160.6, 147.9, 142.1, 139.6, 137.2, 123.6, 122.1, 119.6, 85.9, 58.0, 27.8, 19.8; HRMS (EI-TOF) calcd for $\text{C}_{14}\text{H}_{13}\text{IN}_2\text{OS}(\text{M}^+)$: 385.9950, found:385.9947.


3-Iodo-N-(2-(pyridin-2-yl)propan-2-yl)benzo[b]thiophene-2-carboxamide (3w)



^1H NMR (400 MHz, CDCl_3) δ 9.05 (brs, 1H), 8.56 (m, 1H), 7.89 – 7.85 (m, 1H), 7.83 – 7.78 (m, 1H), 7.75 (ddd, $J=8.0$, 7.6, 1.8 Hz, 1H), 7.51 – 7.42 (m, 3H), 7.22 (ddd, $J=7.6$, 4.8, 0.8 Hz, 1H), 1.92 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.1, 160.9, 147.8, 141.9, 139.2, 138.9, 137.4, 127.4, 127.1, 125.8, 122.6, 122.2, 119.6, 80.1, 58.2, 27.7; HRMS (EI-TOF) calcd for $\text{C}_{17}\text{H}_{15}\text{IN}_2\text{OS}(\text{M}^+)$: 421.9950, found:421.9948.


2,5-Dichloro-4-iodo-N-(2-(pyridin-2-yl)propan-2-yl)thiophene-3-carboxamide

(3p)



^1H NMR (400 MHz, CDCl_3) δ 8.52 – 8.47 (m, 1H), 8.43 (brs, 1H), 7.78 – 7.71 (m, 1H), 7.46 (d, $J=8.0$ Hz, 1H), 7.24 – 7.18 (m, 1H), 1.88 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 163.8, 160.8, 147.6, 139.4, 137.5, 129.1, 125.9, 122.3, 119.6, 81.9, 57.6, 27.6; HRMS (EI-TOF) calcd for $\text{C}_{13}\text{H}_{11}\text{Cl}_2\text{IN}_2\text{OS}(\text{M}^+)$: 439.9014, found:439.9012.


2-Chloro-5-methoxy-N-(2-(pyridin-2-yl)propan-2-yl)benzamide (4e)



^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, $J=4.8$ Hz, 1H), 8.39 (brs, 1H), 7.75 – 7.69 (m,


1H), 7.46 (d, $J = 8.0$ Hz, 1H), 7.28 (d, $J = 8.8$, 1H), 7.21– 7.16 (m, 2H), 6.88 (dd, $J = 8.8, 3.2$ Hz, 1H), 3.81 (s, 3H), 1.89 (s, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ 165.7, 164.37, 158.57, 147.87, 137.5, 137.3, 131.1, 122.1, 122.1, 119.6, 117.5, 114.5, 57.7, 55.8, 27.7; HRMS (EI-TOF) calcd for $\text{C}_{16}\text{H}_{17}\text{ClN}_2\text{O}_2$ (M^+): 304.0979, found:304.0976.

5-Bromo-2-chloro-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (4f)




^1H NMR (400 MHz, CDCl_3) δ 8.53 – 8.44 (m, 2H), 7.77 – 7.71 (m, 2H), 7.46 (m, 1H), 7.44 (d, $J = 2.4$ Hz 1H), 7.27 (d, $J = 8.4$ Hz, 1H), 7.20 (ddd, $J = 7.2, 4.8, 0.8$ Hz, 1H), 1.88 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.4, 163.9, 147.7, 138.6, 137.4, 133.7, 132.5, 131.7, 129.9, 122.2, 120.7, 119.6, 57.7, 27.5; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{BrClN}_2\text{O}$ (M^+): 351.9978, found: 351.9975.

2,5-Dichloro-*N*-(2-(pyridin-2-yl)propan-2-yl)benzamide (4o)




^1H NMR (400 MHz, CDCl_3) δ 8.49 (d, $J = 4.0$ Hz, 2H), 7.77 – 7.71 (m, 1H), 7.60 (d, $J = 2.4$ Hz, 1H), 7.45 (d, $J = 8.4$ Hz, 1H), 7.34 (d, $J = 8.8$ Hz, 1H), 7.32 – 7.28 (m, 1H), 7.23 – 7.17 (m, 1H), 1.88 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 164.6, 164.06, 147.76, 138.36, 137.46, 133.16, 131.5, 130.8, 129.7, 129.3, 122.2, 119.6, 57.7, 27.6; HRMS (EI-TOF) calcd for $\text{C}_{15}\text{H}_{14}\text{Cl}_2\text{N}_2\text{O}$ (M^+): 308.0483, found:308.0486.

2.5 Removal of the Directing Group




To a 50 mL Schlenk tube was added 2c (0.2 mmol) (or 3c) and conc. HCl (3 mL). The mixture was then heated at 145 °C for 48 hours. After cooling down to room temperature, aqueous NaOH (1 M) was added and the aqueous phase was extracted with DCM (10 mL x 2). Then, conc. HCl was added slowly into the aqueous phase (pH = 2) and the aqueous phase was as extracted with DCM (10 mL x 3). The combined organic phase was dried with anhydrous sodium sulfate. After concentration, the desired product **5** was obtained as a white solid.

2-Bromobenzoic acid **5a**



¹H NMR (400 MHz, CDCl₃) δ 11.23 (brs, 1H), 8.05 – 7.99 (m, 1H), 7.72 (dd, *J* = 7.2, 1.6 Hz, 1H), 7.41 (m, 2H).

2-Iodobenzoic acid **5b**





¹H NMR (400 MHz, CDCl₃) δ 8.07 (dd, *J* = 8.0, 1.2 Hz, 1H), 8.03 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.45 (td, *J* = 7.6, 1.2 Hz, 1H), 7.21 (td, *J* = 7.6, 1.6 Hz, 1H).

3. References:

1. K. M. Yager, E. A. Plaza, D. V. Kumar and I. C. Kim, US Pat., 20080207573 A1.
2. F-J. Chen, S. Zhao, F. Hu, K. Chen, Q. Zhang, S-Q. Zhang and B-F. Shi, Chem. Sci., 2013, **4**, 4187
3. B. Li, B. Liu and B-F.Shi, Chem. Commun., 2015, **51**, 5093.

4. NMR Spectra


2a





Cc1cc(C)c(C)c(C)c1C(=O)c2cc(F)cc(Br)c2

¹H NMR spectrum (CDCl₃) of 2-bromo-3-(2,4,6-trimethylphenyl)-4-fluorobenzoic acid. The spectrum shows peaks in the aromatic region (7.0-8.5 ppm) and aliphatic region (1.0-2.0 ppm). Integration values are provided below the peaks.



Chemical Shift (ppm)	Integration
8.467	1.00
8.465	0.95
8.453	
8.439	
7.760	
7.755	
7.740	
7.737	1.03
7.734	1.04
7.717	
7.684	
7.463	2.04
7.452	
7.437	
7.420	
7.390	
7.385	
7.329	
7.214	
7.208	
7.177	
7.170	
7.189	
7.179	
7.174	
7.104	
7.102	
7.083	
7.063	
7.060	
1.910	6.20
1.20	
0.90	
0.00	





2c





2c'





2d





2e





2f



2g



2g'




CC1=CC=CC=C1N(C(C)C)C(=O)c2cc(Br)cc(Br)c2



Chemical structure: 2-(4,6-dibromophenyl)-N-(2,2-dimethylpyridin-5-yl)acetamide

¹H NMR spectrum (CDCl₃) showing peaks in the aromatic region (7.1-8.5 ppm) and an aliphatic region (1.0-2.1 ppm). Integration values are provided below the peaks.



Chemical Shift (ppm)	Integration
8.475, 8.463	0.99
8.353, 8.348, 8.338, 8.322, 8.318, 8.303	0.99
7.738, 7.722, 7.718, 7.703, 7.676, 7.672, 7.648, 7.645, 7.618, 7.597, 7.586, 7.566, 7.524, 7.504, 7.498	1.97
7.493, 7.476, 7.472, 7.448, 7.445, 7.418, 7.397, 7.386, 7.366, 7.324, 7.304, 7.298	1.99
7.186	1.00
2.078	5.87
1.878	
1.078	
0.878	





2h'





2i





2i'





2j





2k





2k'





21





2p





2q





2r





2s





2t





3a





3b





3c





3c'





3e





3g





3h





3m





3n





3u





3v





3w



3p




4e



CN(C)(Cc1ccncc1)C(=O)c2cc(Br)ccc2Cl

¹H NMR spectrum (CDCl₃) of N-(2-bromo-4-chlorophenyl)-2-methyl-2-phenylacetamide. The spectrum shows aromatic signals between 7.1 and 8.5 ppm and a singlet at 1.88 ppm. Integration values are provided for the aromatic region.

Chemical Shift (ppm)	Integration
8.492, 8.491, 8.489, 8.488, 8.486, 8.479	1.87
7.758, 7.749, 7.748, 7.744, 7.724, 7.720	1.93
7.664, 7.653, 7.643, 7.637, 7.625, 7.620, 7.618, 7.608, 7.606, 7.603, 7.600, 7.589, 7.587	0.88, 0.86, 1.14, 1.00
1.881	6.01




CN(C)(C)c1ccncc1C(=O)c2cc(Cl)cc(Cl)c2


Chemical structure: N-(2,4-dichlorophenyl)-2,2-dimethylpyridin-4-amine

¹H NMR spectrum (CDCl₃) showing peaks in the aromatic region (7.1-8.5 ppm) and a dimethylamino group region (2.8-3.0 ppm). Integration values are provided below the peaks.

Chemical Shift (ppm)	Integration
8.490	1.89
7.762	1.02
7.742	0.94
7.739	1.01
7.738	0.95
7.721	0.99
7.607	1.01
7.463	
7.349	
7.327	
7.314	
7.293	
7.292	
7.287	
7.266	
7.206	
7.205	
7.200	
7.188	
2.881	6.05



5a



5b

